Trial Profile
A clinical study of mRNA-3927 for the treatment of patients with Propionic Acidemia (PA) and methylmalonic acidaemia (MMA)
Status:
Recruiting
Phase of Trial:
Phase I
Latest Information Update: 16 Jul 2018
Price :
$35
*
At a glance
- Drugs MRNA-3927 (Primary)
- Indications Methylmalonic acidaemia; Propionic acidaemia
- Focus Adverse reactions
- Acronyms MaP Study
- 16 Jul 2018 New trial record
- 11 Jul 2018 According to a Moderna Therapeutics media release, he company has enrolled the first patients in this study.